Artivion (NYSE:AORT) Given New $30.00 Price Target at Stifel Nicolaus

Artivion (NYSE:AORT) had its price target lowered by Stifel Nicolaus from $33.00 to $30.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 7.53% from the company’s current price.

Several other research firms have also commented on AORT. Oppenheimer upped their price objective on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and set a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Finally, Needham & Company LLC dropped their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $31.40.

Artivion Stock Performance

Shares of AORT stock opened at $27.90 on Tuesday. The stock has a market cap of $1.17 billion, a PE ratio of -1,394.90 and a beta of 1.75. Artivion has a 52-week low of $18.38 and a 52-week high of $32.33. The business has a 50-day simple moving average of $29.75 and a 200-day simple moving average of $27.83. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71.

Insider Activity

In related news, CAO Amy Horton sold 4,329 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the transaction, the chief accounting officer now owns 135,660 shares in the company, valued at $4,023,675.60. This represents a 3.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jean F. Holloway sold 8,070 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the completion of the transaction, the senior vice president now directly owns 153,862 shares in the company, valued at $4,634,323.44. This represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,017 shares of company stock worth $600,007 in the last quarter. Corporate insiders own 8.10% of the company’s stock.

Institutional Trading of Artivion

Large investors have recently made changes to their positions in the company. FMR LLC lifted its holdings in Artivion by 28.0% in the 3rd quarter. FMR LLC now owns 115,184 shares of the company’s stock valued at $3,066,000 after purchasing an additional 25,176 shares in the last quarter. Barclays PLC lifted its stake in shares of Artivion by 346.3% in the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock worth $1,888,000 after buying an additional 54,996 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in Artivion during the third quarter worth about $5,798,000. JPMorgan Chase & Co. grew its stake in Artivion by 394.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock valued at $2,606,000 after acquiring an additional 78,120 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Artivion by 58.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after acquiring an additional 125,668 shares during the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.